Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-263542
Filing Date
2025-11-04
Accepted
2025-11-04 07:11:45
Documents
83
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q beam-20250930.htm   iXBRL 10-Q 2967867
2 EX-31.1 beam-ex31_1.htm EX-31.1 19594
3 EX-31.2 beam-ex31_2.htm EX-31.2 29664
4 EX-32.1 beam-ex32_1.htm EX-32.1 11737
5 EX-32.2 beam-ex32_2.htm EX-32.2 10855
  Complete submission text file 0001193125-25-263542.txt   12105028

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT beam-20250930.xsd EX-101.SCH 1518630
86 EXTRACTED XBRL INSTANCE DOCUMENT beam-20250930_htm.xml XML 2508362
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 857-327-8775
Beam Therapeutics Inc. (Filer) CIK: 0001745999 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39208 | Film No.: 251446429
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)